Board of Directors
Steve Engle – Non-Executive Chairman
Steve Engle is CEO of Averigon Consulting, an advisory firm to the life science industry. Previously, Mr. Engle was Chairman and CEO of XOMA, a developer of antibody therapeutics for inflammatory, metabolic, oncology and other diseases. Prior to that, he was Chairman and CEO of La Jolla Pharmaceutical Company, which discovered the biology of B cell tolerance, developed the first B cell toleragen for lupus patients, and received an approvable letter from the FDA. Mr. Engle served as VP of Marketing for Cygnus, a drug delivery company, where he helped gain FDA approval of and launch Nicotrol for smoking cessation. He was VP of Marketing at a $50 million device company and a management consultant at Strategic Decisions Group and SRI (Stanford Research Institute) International.
Mr. Engle is a board member of Prescient Therapeutics, AROA Biosurgery, a developer of regenerative medicine products, and Author-it Software Corporation, a developer of authoring information solutions for pharmaceutical and biotechnology companies. Mr. Engle is a former board member of BIO, Baybio, and BIOCOM, and the Lupus Foundation of America. Mr. Engle holds a B.S. and an M.S. in electrical engineering with a focus in biomedical engineering from the University of Texas at Austin.
Steven Yatomi-Clarke – CEO and Managing Director
Steven Yatomi-Clarke has a distinguished career in the Australian capital markets with a particular focus on the life sciences sector, where he has played a leading role as both a corporate advisor and fund raiser to many biotechnology companies. Mr Yatomi-Clarke previously held a position as a Director in Corporate Finance at Patersons Securities.
Educated at the University of Melbourne, where he earned a Bachelor of Science with an Honours Degree in Biochemistry and Molecular Biology, and a Bachelor Commerce majoring in Economics, he has the rare distinction of readily bridging the divide between science and commerce.
He has a strong track record of financing multiple private and public biotechnology companies, bringing more than 15 years’ experience in investment banking with a particular focus on the life sciences/biotechnology sector.
Mr Yatomi-Clarke has consistently been one of the country’s most prolific bankers, involved in primary and secondary offerings, corporate advisory and M&A assignments for medical device and pharmaceutical companies.
Paul Hopper – Executive Director
Mr Hopper has international & ASX biotech capital markets experience, particularly in oncology. He is the former Chairman of Viralytics (acquired in June 2018 by Merck for $500m), Founder & Director of Prescient, Founder of Imugene & Polynoma LLC, former Director pSivida, Somnomed & Fibrocell Science.
Dr James Campbell – Non-Executive Director
Dr James Campbell brings to Prescient a solid track record as a scientist and commercial executive. He was previously the Chief Financial Officer and Chief Operating Officer of Chemgenex, which was acquired by Cephalon for $230 million in 2011.
His responsibilities ranged from IP management to licensing and business development and as a member of the executive team, he helped steer and transform the company from a $10 million research based entity to a company with completed clinical trials and regulatory dossiers submitted to the FDA and EMA before its $230 million sale.
More recently he guided the creation of Invion Limited (ASX: IVX) as a non-executive director and retains this role.
Dr Campbell also has experience advising private biotechnology companies in the US and New Zealand with capital raisings and partnering negotiations.